Advancement of NPT200-11 into Preclinical Development

Posted on January 30, 2014

San Diego, CA - NeuroPore Therapies, a San Diego based biopharmaceutical company dedicated to the discovery and development of novel therapeutics for neurodegenerative disorders, with support from the Michael J. Fox foundation, has initiated preclinical development of its lead compound for the treatment of Parkinson’s disease. This novel compound, NPT200-11, blocks the pathological protein misfolding, aggregation and deposition that contributes to synaptic dysfunction and cell death in Parkinson’s disease and related disorders. Moreover, NPT200-11 is orally bioavailable, has promising drug-like properties and, has shown robust beneficial actions on multiple endpoints in animal models. It is the goal of Neuropore therapies to advance NPT200-11 into clinical trials for evaluation as a novel therapeutic for Parkinson’s disease.

For Further Information

Media Contact Neuropore:

Dieter Meier, MD
Chief Executive Officer

Phone: +1 858-273-1831

Back to News